# Invert **Source:** https://geo.sig.ai/brands/invert **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** invertbio.com **Last Updated:** 2026-04-14 ## Summary AI bioprocessing data platform for cellular agriculture and synthetic biology optimizing fermentation with 90% data reduction; $20.6M raised at $5M revenue serving industrial biotech scale-up. ## Company Overview Invert is a San Francisco-based AI software company providing data analytics and process optimization infrastructure for biomanufacturing — enabling bioprocessing teams at cellular agriculture, synthetic biology, and industrial biotech companies to manage, analyze, and optimize their bioprocess data in real-time. Founded and backed with $20.6 million raised, Invert generates $5 million in revenue and employs 40 people, applying meta-learning approaches that reportedly reduce new data requirements for process optimization by up to 90%. Invert's platform addresses the data fragmentation problem endemic to bioprocessing operations: bioreactor runs generate streams of sensor data (dissolved oxygen, pH, temperature, cell density, metabolites) from multiple instruments and information systems that are typically stored in disconnected databases, spreadsheets, and lab notebooks. Invert integrates these disparate data sources into a unified operational data platform, applies AI models trained across biomanufacturing datasets to identify process parameters that predict product quality, and provides the analytics interface that scientists and process engineers use to optimize fermentation conditions and scale processes from lab to production. In 2025, Invert competes in the bioprocess data analytics and manufacturing intelligence market with Sartorius' Ambr systems (automated bioreactor screening with data analytics), Cytovance Biologics (CDMO data services), and emerging bioprocess AI platforms for biomanufacturing process optimization software. The bioprocessing data market has expanded significantly as cell-cultured meat, biofuel, and synthetic biology applications have attracted billions in investment — all requiring the same bioprocess scale-up challenge of moving from research-scale fermentation to commercial production while maintaining product quality. Invert's meta-learning approach (transferring learnings across bioproduction contexts) provides an advantage for customers with limited proprietary data. The 2025 strategy focuses on cellular agriculture and industrial fermentation growth, deepening partnerships with bioreactor equipment manufacturers, and building the bioprocess digital twin that simulates production optimization. ## Frequently Asked Questions ### What is Invert? Invert is a San Francisco-based biomanufacturing data analytics company founded in 2021 that builds purpose-built Bioprocess AI Software. The company transforms fragmented bioprocess data into real-time insights and AI-driven decisions for bio-industrial manufacturers. ### What products and services does Invert offer? Invert offers Bioprocess AI Software that includes bioprocessing data management, real-time bioreactor insights, AI-driven optimization, and meta-learning data leverage capabilities. Their software helps manage, analyze, and optimize bioprocessing data for bioreactor operations. ### Who are Invert's target customers? Invert serves bio-industrial companies in the cellular agriculture, synthetic biology, and industrial biotech sectors. Their customers are bio-manufacturers who require reliable data management and analytics for bioreactor operations. ### When was Invert founded? Invert was founded in 2021 and participated in Y Combinator's W22 batch. ### Where is Invert located? Invert is based in San Francisco, California. ### How much funding has Invert raised? Invert has raised $20.6M in total funding over 2 rounds from 3 investors. The most recent round was a $20.1M exempt offering in New Equity Investment in July 2024, with investors including Y Combinator, ACME, and Giant Ventures. ### What are Invert's key metrics and achievements? As of June 2024, Invert reached $5M in revenue with 40 employees. Their meta-learning approach enables bio-manufacturers to cut new data needs by up to 90% by leveraging older project data. ### What technology approach does Invert use? Invert uses a meta-learning approach that allows bio-manufacturers to leverage older project data, reducing new data requirements by up to 90%. This AI-driven technology provides real-time insights and optimization for bioprocessing operations. ### How does Invert's meta-learning technology benefit customers? Invert's meta-learning approach enables bio-manufacturers to leverage data from older projects, cutting the need for new data by up to 90%. This significantly accelerates the optimization process for bioreactor operations. ### What are Invert's recent developments? Recent developments include reaching $5M in revenue by June 2024 and completing a $20.1M funding round in July 2024. The company has grown to 40 employees while serving bio-industrial customers across cellular agriculture, synthetic biology, and industrial biotech sectors. ## Tags healthtech, b2b, north-america --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*